CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,120 enrolled
Drug / intervention
Lansoprazoledrug
Likely dose
Lansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02151786
NCT02151786N/ACompleted
CompareCT.gov

Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

Takeda·observational·Posted May 30, 2014·Updated Feb 23, 2016

In Brief

An observational study evaluating Lansoprazole for Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions. Completed, enrolled 1,120 participants.

Detailed Summary

The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg) to a large number of patients in daily medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2014
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.1 years ago

Interventions

Lansoprazoledrug

Lansoprazole intravenous 30 mg